Thu.Dec 16, 2021

article thumbnail

Answer of the Day for Dec 17, 2021

TheAnswerPage

What is the most common non-serious adverse event associated with the use of medical marijuana products? Dizziness is the most common non-serious adverse event. Other non-serious adverse events include nausea, sleepiness, confusion and anxiety. Busse J W, Vankrunkelsven P, Zeng L, Heen A F, Merglen A, Campbell F et al.

article thumbnail

The Week in Weed: December 17, 2021

The Blunt Truth

Further bulletins as events warrant. Rhode Island will have to wait until 2022 for the answer to that question. Legislators are getting closer to an agreement, but they’re not quite there yet. A hemp research farm in Princeton, Kentucky was completely destroyed by the tornado that ripped through the area last weekend.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Frost Exotic Cannabis Announces New Delivery Service Available in Denver

Cannabis Law Report

The Frost Exotic Cannabis popup continues to marry world class customer service with premium products and hand selected flower of the highest quality, while surprising and delighting guests with Frosty collaborations, unique strains, exclusive releases and special events. Media Contact: Brian Bock. Grasslands: A Journalism-Minded Agency.

article thumbnail

How to (Prepare to) Open a Psilocybin Business in Oregon Under Measure 109

Cannabis Law Report

Finally, keep abreast of the Oregon Health Authority rulemaking process, and participate in any public-facing events the agency holds, such as the listening sessions set for December 13-15, 2021. To be clear, we do not recommend this approach!

article thumbnail

The Alkaline Water Company Sends Its First Orders of A88CBD™ FreshCap™ Powered by Vessl® to Multiple Distributors

Cannabis Law Report

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that there will be increased production capacity through implementation of (..)

Retail 52